

1. A vaccine composition comprising a major outer membrane protein (MOMP) from Chlamydia in conjunction with a mucosal adjuvant, which induces a MOMP antigen specific TH1-like immune response.

- 25

12. A vaccine as claimed in any of claims 1 to 4 adapted for systemic administration.
13. A delivery device pre-filled with the vaccine of claim 1, said device being designed to administer the vaccine systemically.
14. A vaccine as claimed in any of claims 1 to 4 wherein the outer membrane protein is produced in *E. coli* by recombinant DNA technology.
15. A process for the production of a vaccine comprising admixing a mucosal adjuvant with a MOMP from *Chlamydia*.
16. A method of inducing heterotypic prophylaxis of *Chlamydia* infection comprising administering to a patient a safe and effective amount of a vaccine composition of claims 1-4.
17. A method of inducing heterotypic prophylaxis of *Chlamydia* induced infertility comprising administering to a patient a safe and effective amount of a vaccine composition of claims 1-4.